PRF Technologies Ltd. (PRFX)
| Market Cap | 3.13M +17.0% |
| Revenue (ttm) | 17,000 |
| Net Income | -4.84M |
| EPS | -7.47 |
| Shares Out | 3.04M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 64,233 |
| Open | 1.050 |
| Previous Close | 1.100 |
| Day's Range | 1.020 - 1.075 |
| 52-Week Range | 0.970 - 17.950 |
| Beta | 1.04 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Sep 30, 2026 |
About PRFX
PRF Technologies Ltd., a specialty pharmaceutical company, focuses on reformulation of established therapeutics in Israel. It develops OcuRing-K, a bio-erodible sustained-release implant applied to the haptic of an intraocular lens for use in cataract surgery; and PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company was formerly known as PainReform Ltd. and changed its name to PRF Technologies Ltd. in January 2026. PRF Technologies ... [Read more]
Financial Performance
Financial StatementsNews
PRF Technologies Issues Letter to Shareholders Highlighting Strengthened Financial Position and Building Momentum Across Its Biotechnology and AI-Driven Energy Platforms
Interim CEO Efraim Cohen-Arazi Details $10 Million in New Capital, LayerBio's Preparations for the Planned Phase 2 Clinical Trial of OcuRing™-K, and DeepSolar's Advance Toward Commercial Launch Interi...
PRF Technologies to Showcase GridFeed™ at Energy Trading Week Europe 2026
TEL AVIV, Israel, July 21, 2026 (GLOBE NEWSWIRE) -- PRF Technologies Ltd. (Nasdaq: PRFX) (“PRF” or the “Company”) today announced that its DeepSolar business unit will participate in Energy Trading We...
PRF Technologies Expands DeepSolar Predict™ Platform with Battery-to-Revenue Intelligence, Extending AI-Driven Revenue Optimization Across Solar and Energy Storage Assets
New Capability Builds on Recently Completed Real-World Validation of DeepSolar Predict™ as the Solution Advances Toward Planned Commercial Launch New Capability Builds on Recently Completed Real-World...
PRF Technologies' DeepSolar Successfully Validates Predict™ AI Platform for Renewable Energy Revenue Optimization Using Real-World European Market Data
Validation Applied Utility-Scale Renewable Production, Weather and Market Data Across Day-Ahead and Intraday Scenarios as the Solution Advances Toward Planned Commercial Launch Validation Applied Util...
PRF Technologies announces expanded results from PRF-110 study
PRF Technologies (PRFX) announced expanded results from its previously reported preclinical study directly comparing its lead product candidate, PRF-110, to Zynrelef, an approved extended-release prod...
PRF Technologies Reports Expanded Preclinical Results for PRF-110 in Head-to-Head Comparison with Approved Benchmark
Additional data reported by an independent research firm show comparable analgesic efficacy to ZYNRELEF alongside slower absorption and enhanced local tissue retention, reinforcing PRF-110's potential...
PRF Technologies files to sell 7.5M ordinary shares for holders
16:18 EDT PRF Technologies (PRFX) files to sell 7.5M ordinary shares for holders
Why Is Penny Stock PRF Technologies (PRFX) Up Today?
PRF Technologies stock was up alongside an update on its renewable energy AI platform.
PRF Technologies Advances DeepSolar Predict™ Toward Commercial Launch as AI Platform Targets Revenue Optimization Across Renewable Energy Markets
Platform builds on NVIDIA Connect participation and previously announced weather-domain patent filing to address forecasting accuracy, imbalance exposure, storage optimization and real-time market dec...
PRF Technologies announces results from study comparing PRF-110 to Zynrelef
PRF Technologies (PRFX) announced positive results from a preclinical study in domestic pigs directly comparing its lead product candidate, PRF-110, to Zynrelef, an approved extended-release product u...
PRF Technologies Announces PRF-110 Demonstrated Sustained 72-Hour Analgesic Activity Comparable to Approved, Commercially Available Benchmark in Head-to-Head Preclinical Study
Ropivacaine-only, NSAID-free formulation leverages a long-acting local anesthetic with a favorable safety profile Ropivacaine-only, NSAID-free formulation leverages a long-acting local anesthetic with...
PRF Technologies registers to sell 3M ordinary shares for holders
This filing relates to the offer and sale from time to time by the selling stockholder of up to 3M ordinary shares. The company is not selling any shares under…
PRF Technologies announces FDA clearance of OcuRing-K NDA
PRF Technologies (PRFX) announced that the FDA has cleared the company’s investigational new drug application for OcuRing-K, enabling the initiation of a Phase II clinical trial in patients undergoing...
PRF Technologies Announces FDA Clearance of IND Application for OcuRing™-K Phase II Clinical Trial
Milestone supports advancement of PRF's drop-less ocular drug-delivery platform into next-stage U.S. clinical development for post-cataract pain and inflammation Milestone supports advancement of PRF'...
PRF Technologies Provides Year-End 2025 Business Update Highlighting Strategic Progress Across Healthcare and AI-Driven Solar Platforms
LayerBio's OcuRing™-K program and broader ocular platform strengthen PRF's healthcare growth strategy DeepSolar advances from acquisition to early commercial deployment TEL AVIV, Israel, March 27, 202...
PRF Technologies signs commercial collaboration agreement with Blade Ranger
PRF Technologies (PRFX) announced a commercial collaboration agreement with Blade Ranger designed to accelerate the commercial expansion of its DeepSolar platform across utility-scale solar portfolios...
PRF Technologies Ltd. Announces Commercial Collaboration Agreement with Blade Ranger to Accelerate Large-Scale DeepSolar Commercial Engagements
TEL AVIV, Israel, March 17, 2026 (GLOBE NEWSWIRE) -- PRF Technologies Ltd. (Nasdaq: PRFX) (“PRF” or the “Company”) today announced a commercial collaboration agreement with Blade Ranger Ltd.
PRF Technologies’ DeepSolar announces commercial due diligence engagement
PRF Technologies (PRFX) announced that its DeepSolar business unit has entered into a solar analytics services agreement with a subsidiary of EDF Group relating to an operational, utility-scale solar ...
PRF Technologies' DeepSolar Announces its First Commercial Due Diligence Engagement with EDF Power Solutions Israel, a Global Leader in Renewable Energy
Agreement Initiates Data-Driven Technical Due Diligence of an Operational, Utility-Scale Solar Asset in Israel Agreement Initiates Data-Driven Technical Due Diligence of an Operational, Utility-Scale ...
PRF Technologies signs SaaS agreement with Shikun & Binui Energy
PRF Technologies (PRFX) announced the signing of a software-as-a-service, SaaS, agreement with Shikun & Binui Energy for the deployment of DeepSolar at the 71 megawatt, MW, Satu Mare photovoltaic site...
PRF Technologies Wins Another European Utility-Scale Solar Deployment, Expanding DeepSolar's Installed Commercial Base
TEL AVIV, Israel, Feb. 11, 2026 (GLOBE NEWSWIRE) -- PRF Technologies (Nasdaq: PRFX) (“PRF” or the “Company”), through its DeepSolar™ AI-driven solar analytics business unit, today announced the signin...
PRF Technologies Ltd trading halted, news pending
19:50 EST PRF Technologies (PRFX) Ltd trading halted, news pending
PRF files first patent application for solar plant-level micro-climate modeling
PRF Technologies (PRFX) announced that it has filed a patent application covering proprietary methods for solar plant-level micro-climate modeling designed to significantly improve the accuracy of sol...
PRF Technologies Files Its First Patent Application for Solar Plant Micro-Climate Forecast Modeling Designed to Improve Energy Production Forecast Accuracy
Patent filing follows acceptance into the NVIDIA Connect Program Proprietary software targets weather forecast-driven revenue optimization, reduced penalty risk, and improved market performance for u...
PainReform changes name to PRF Technologies
PainReform announced its corporate name change to PRF Technologies following shareholder approval at the company’s annual general meeting. The company’s Nasdaq ticker symbol will remain (PRFX).